Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8690 phase 2 trial in moderately to severely active ulcerative colitis
NL-OMON61307Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aprepitant in autoimmune colitis (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of participants achieving clinical remission per Modified Mayo Score at Week 12. Started Jun 2026; status: recruiting.
02
Drugs
aprepitant
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON61307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61307.